Açıklama

Cyclosporine, a strong dual inhibitor of CYP3A4 and P-glycoprotein, substantially increases rivaroxaban exposure and bleeding risk.

Mekanizma

Rivaroxaban depends on CYP3A4 for metabolism and P-gp for intestinal efflux; cyclosporine inhibits both, increasing rivaroxaban AUC by up to 50%.

Klinik Önemi

This combination is generally contraindicated in post-transplant patients who may also have organ-specific bleeding risks.

Yönetim

Avoid combination; consider alternative anticoagulation strategies in transplant recipients requiring anticoagulation.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.